Send to

Choose Destination
Ugeskr Laeger. 2009 Nov 16;171(47):3435-7.

[Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review].

[Article in Danish]

Author information

Øjenafdelingen, Glostrup Hospital, DK-2600 Glostrup, Denmark.


This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center